目的原发性乳腺淋巴瘤(primary breast lymphoma,PBL)是一种罕见的血液系统疾病,在临床上常与乳腺恶性肿瘤混淆。本研究分析近5年国内外有关PBL的研究,明确其诊断、治疗以及预后的特点,提高临床工作中对PBL的认识。方法应用PubMed、中...目的原发性乳腺淋巴瘤(primary breast lymphoma,PBL)是一种罕见的血液系统疾病,在临床上常与乳腺恶性肿瘤混淆。本研究分析近5年国内外有关PBL的研究,明确其诊断、治疗以及预后的特点,提高临床工作中对PBL的认识。方法应用PubMed、中国知网以及万方数据库检索系统,以中文关键词“乳腺、淋巴瘤”和英文关键词“breast、lymphoma、diagnosis、treatment”,检索2014-01-2019-08发表的相关文献,共检索中文文献105篇,英文文献289篇。纳入标准:(1)与PBL的诊断、治疗以及预后有关的研究;(2)有特色的个案研究;(3)病例数较多的临床实验。排除标准:(1)非中文核心期刊和英文非SCI收录的文献;(2)作者所属单位为基层医院;(3)结果重复且相对陈旧的临床实验。根据纳入和排除标准,最终38篇文献纳入分析。结果PBL是指在没有先前诊断为乳房外淋巴瘤且同时不存在其他广泛疾病的情况下发生在乳房中的原发性淋巴瘤,其发病率低,容易与乳腺癌混淆。PBL女性的发病率高,一般以单侧乳房肿块为首发症状;影像学诊断缺乏特异性,细针穿刺及病理学检查为金标准;局部手术可用于病理诊断,化疗联合靶向治疗是目前的主要治疗方式,辅助放疗可以改善PBL患者的预后,降低复发风险,但是对于预防性鞘内注射目前有很大争议;预后与病理类型、临床分期以及是否有结外器官受累有关。结论PBL的发病率低,确诊需要依靠病理学检查,临床中有可疑的淋巴瘤患者应与乳腺癌患者区分,避免误诊。展开更多
乳腺淋巴瘤包括原发性乳腺淋巴瘤(primary breast lymphoma,PBL)和继发性乳腺淋巴瘤其中BL是以乳腺为原发部位的恶性淋巴瘤,属于结外型淋巴瘤,其病理类型多为非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL),极少为霍奇金淋巴瘤.原发乳腺NHL...乳腺淋巴瘤包括原发性乳腺淋巴瘤(primary breast lymphoma,PBL)和继发性乳腺淋巴瘤其中BL是以乳腺为原发部位的恶性淋巴瘤,属于结外型淋巴瘤,其病理类型多为非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL),极少为霍奇金淋巴瘤.原发乳腺NHL中以弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)最常见[1],其发病率均比乳腺癌低,临床上仅根据影像学资料很难与乳腺癌鉴别.乳腺淋巴瘤和乳腺癌的治疗方法及预后截然不同,术前如有疑诊为乳腺淋巴瘤的患者应高度警惕.展开更多
The present study was designed to determine the major chemical constituents of the leaves of Rhododendron dauricum L. Compounds were isolated and purified by various chromatographic methods, and their structures were ...The present study was designed to determine the major chemical constituents of the leaves of Rhododendron dauricum L. Compounds were isolated and purified by various chromatographic methods, and their structures were elucidated by physicochemical properties and spectral data. The present study identified two new C-methyl flavanones, 5, 7, 3', 5'-tetrahydroxy-6, 8-di-C-methyl flavanone(1) and 5, 4'-dihydroxy-8-C-methylflavanone-7-O-β-D-glucopyranoside(2), and one new flavonoid glycoside, quercetin-3-O-β-D-(6''-O-cinnamoyl)-galactoside(3), along with seven known compounds, including syzalterin(4), poriolin(5), farrerol-7-O-β-D-glucopyranoside(6), myrciacetin(7), quercetin-3-O-β-D-(6-p-hydroxy-benzoyl)-galactoside(8), quercetin-3-O-β-D-(6-p-coumaroyl)-galactoside(9), and 5, 7, 3', 5'-tetrahydroxyl flavanone(10). Compounds 1-3 were determined to be new flavonoids; compounds 4-6 were isolated from this species for the first time; and compounds 7-10 were reported for the first time from this genus.展开更多
文摘目的原发性乳腺淋巴瘤(primary breast lymphoma,PBL)是一种罕见的血液系统疾病,在临床上常与乳腺恶性肿瘤混淆。本研究分析近5年国内外有关PBL的研究,明确其诊断、治疗以及预后的特点,提高临床工作中对PBL的认识。方法应用PubMed、中国知网以及万方数据库检索系统,以中文关键词“乳腺、淋巴瘤”和英文关键词“breast、lymphoma、diagnosis、treatment”,检索2014-01-2019-08发表的相关文献,共检索中文文献105篇,英文文献289篇。纳入标准:(1)与PBL的诊断、治疗以及预后有关的研究;(2)有特色的个案研究;(3)病例数较多的临床实验。排除标准:(1)非中文核心期刊和英文非SCI收录的文献;(2)作者所属单位为基层医院;(3)结果重复且相对陈旧的临床实验。根据纳入和排除标准,最终38篇文献纳入分析。结果PBL是指在没有先前诊断为乳房外淋巴瘤且同时不存在其他广泛疾病的情况下发生在乳房中的原发性淋巴瘤,其发病率低,容易与乳腺癌混淆。PBL女性的发病率高,一般以单侧乳房肿块为首发症状;影像学诊断缺乏特异性,细针穿刺及病理学检查为金标准;局部手术可用于病理诊断,化疗联合靶向治疗是目前的主要治疗方式,辅助放疗可以改善PBL患者的预后,降低复发风险,但是对于预防性鞘内注射目前有很大争议;预后与病理类型、临床分期以及是否有结外器官受累有关。结论PBL的发病率低,确诊需要依靠病理学检查,临床中有可疑的淋巴瘤患者应与乳腺癌患者区分,避免误诊。
文摘乳腺淋巴瘤包括原发性乳腺淋巴瘤(primary breast lymphoma,PBL)和继发性乳腺淋巴瘤其中BL是以乳腺为原发部位的恶性淋巴瘤,属于结外型淋巴瘤,其病理类型多为非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL),极少为霍奇金淋巴瘤.原发乳腺NHL中以弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)最常见[1],其发病率均比乳腺癌低,临床上仅根据影像学资料很难与乳腺癌鉴别.乳腺淋巴瘤和乳腺癌的治疗方法及预后截然不同,术前如有疑诊为乳腺淋巴瘤的患者应高度警惕.
基金supported by the National Natural Science Foundation of China(No.81373956)
文摘The present study was designed to determine the major chemical constituents of the leaves of Rhododendron dauricum L. Compounds were isolated and purified by various chromatographic methods, and their structures were elucidated by physicochemical properties and spectral data. The present study identified two new C-methyl flavanones, 5, 7, 3', 5'-tetrahydroxy-6, 8-di-C-methyl flavanone(1) and 5, 4'-dihydroxy-8-C-methylflavanone-7-O-β-D-glucopyranoside(2), and one new flavonoid glycoside, quercetin-3-O-β-D-(6''-O-cinnamoyl)-galactoside(3), along with seven known compounds, including syzalterin(4), poriolin(5), farrerol-7-O-β-D-glucopyranoside(6), myrciacetin(7), quercetin-3-O-β-D-(6-p-hydroxy-benzoyl)-galactoside(8), quercetin-3-O-β-D-(6-p-coumaroyl)-galactoside(9), and 5, 7, 3', 5'-tetrahydroxyl flavanone(10). Compounds 1-3 were determined to be new flavonoids; compounds 4-6 were isolated from this species for the first time; and compounds 7-10 were reported for the first time from this genus.
